Get the Stockscreener App
0.50
13.99%
0.044
After Hours:
.53
0.03
+6.00%
Ainos Inc stock is traded at $0.50, with a volume of 138.58K.
It is up +13.99% in the last 24 hours and up +20.88% over the past month.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
See More
Previous Close:
$0.456
Open:
$0.4798
24h Volume:
138.58K
Relative Volume:
0.70
Market Cap:
$6.62M
Revenue:
$122.10K
Net Income/Loss:
$-13.77M
P/E Ratio:
-0.6579
EPS:
-0.76
Net Cash Flow:
$-4.79M
1W Performance:
+8.52%
1M Performance:
+20.88%
6M Performance:
-36.30%
1Y Performance:
-72.93%
1-Day Range:
$0.461
$0.5299
1-Week Range:
$0.432
$0.5299
52-Week Range:
$0.40
$4.2899
Ainos Inc Stock (AIMD) Company Profile
Name
Ainos Inc
Sector
Industry
Phone
858-869-2986
Address
AINOS, INC., SAN DIEGO
Compare AIMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIMD
Ainos Inc
|
0.50 | 6.62M | 122.10K | -13.77M | -4.79M | -3.41 |
|
ABT
Abbott Laboratories
|
113.47 | 195.63B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
358.95 | 136.44B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
89.37 | 130.98B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
80.20 | 102.47B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.59 | 42.60B | 6.60B | 4.16B | 490.10M | 6.93 |
Ainos Inc Stock (AIMD) Latest News
Short Interest in Ainos, Inc. (NASDAQ:AIMD) Grows By 58.1% - Defense World
AIMDWAinos, Inc. Warrants Latest Stock News & Market Updates - StockTitan
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - AccessWire
Ainos CEO looks to advance AI nose technology in 2025 - TipRanks
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - AccessWire
Short Interest in Ainos, Inc. (NASDAQ:AIMD) Grows By 43.2% - Defense World
Golden Peak Minerals (CVE:GP) Stock Price Down 12.3% – Here’s Why - Defense World
Visionary (NYSEAMERICAN:GV) Stock Price Down 2.2% – What’s Next? - Defense World
Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Large Increase in Short Interest - Defense World
Ainos Enhances Investor Relations with Strategic Webull Corporate Connect Integration - StockTitan
Ainos, Taiwan Tanabe to manufacture low-dose interferon alpha for Sjögren’s - Sjogren's Syndrome News
Ainos Partners with Taiwan Tanabe for VELDONA® Expansion - TipRanks
Ainos Partners with Mitsubishi Subsidiary for Breakthrough Sjögren's Syndrome Treatment VELDONA® - StockTitan
Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren's Drug - Smartkarma
Analyzing the Impact of Earnings Reports on Ainos Inc Inc. (AIMD) Price Performance - The InvestChronicle
Cybeats Partners with Sophic Capital for Capital Markets Services - IT Business Net
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren’s Syndrome Drug - IT Business Net
US-Taiwan partnership to advance manufacturing of Sjögren's Syndrome drug - BSA bureau
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug - RiauGreen.com
Gorilla Technology Group Adds Tech Luminary Thomas Sennhauser to Board of Directors - Media OutReach
Ainos (OTCMKTS:AIMD) Shares Up 3.6% – Here’s What Happened - Defense World
Ainos, Inc. Reports Q3 Financial Results and Strategic Developments - TipRanks
AIMD Stock Hits 52-Week Low at $0.4 Amid Market Challenges - Investing.com India
AIMDAinos, Inc. Latest Stock News & Market Updates - StockTitan
Ainos (AIMD) Advances VELDONA Trial for Sjogren's: Key IRB Approval Secured, 28 Patents Added | AIMDW Stock News - StockTitan
Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest - Defense World
Ainos Advances Sjögren's Treatment: Key Trial for VELDONA® Gets IRB Green Light | AIMDW Stock News - StockTitan
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) - Yahoo Finance
Ainos reports unusual stock activity to regulators - Investing.com India
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - WICZ
Ainos reports unusual stock activity to regulators By Investing.com - Investing.com UK
Ainos (AIMD) Alerts SEC to Suspicious Trading Activity, Demands Investigation | AIMDW Stock News - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 14.7% – Here’s Why - Defense World
Ainos Reports Third Quarter 2024 Financial Results - StockTitan
Behcet's syndrome Treatment Market 2034: Clinical Trials, EMA, - openPR
Ainos stock plunges to 52-week low of $0.45 amid steep annual decline - Investing.com
Analyzing CONMED (NYSE:CNMD) & Ainos (OTCMKTS:AIMD) - Defense World
Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 37.6% in October - Defense World
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets - StockTitan
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - StockTitan
Ainos Inc. secures exclusive patent rights in new deal - Investing.com
Ainos Inc. secures exclusive patent rights in new deal By Investing.com - Investing.com UK
Ainos (OTCMKTS:AIMD) Stock Price Down 8.7% – Here’s Why - Defense World
Ainos Leverages AI Nose for Safer, Smarter Factories - MSN
Financial Health Report: Ainos Inc (AIMD)’s Ratios Tell a Tale - The Dwinnex
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges - GuruFocus.com
Ainos Inc. secures stockholder nod for special stock awards - Investing.com
Ainos planning Phase 3 study of low-dose interferon-alpha for primary Sjögren’s - Sjogren's Syndrome News
Ainos Inc (AIMD) Stock: A Year of Highs and Lows - The InvestChronicle
Ainos Inc Stock (AIMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):